Patents by Inventor Fabienne Kurt

Fabienne Kurt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Consortia of living bacteria useful for treatment of microbiome dysbiosis
    Patent number: 11219649
    Abstract: The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: January 11, 2022
    Assignees: ETH Zurich, UNIVERSITÄT ZÜRICH
    Inventors: Christophe Lacroix, Tomas De Wouters, Gerhard Rogler, Christophe Chassard, Laura Berchtold, Fabienne Kurt, Michael Martin Scharl, Marianne Rebecca Spalinger, Markus Reichlin, Florian Nils Rosenthal, Marco Meola
  • CONSORTIA OF LIVING BACTERIA USEFUL FOR TREATMENT OF MICROBIOME DYSBIOSIS
    Publication number: 20200276250
    Abstract: The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
    Type: Application
    Filed: April 12, 2018
    Publication date: September 3, 2020
    Inventors: Christophe Lacroix, Tomas De Wouters, Gerhard Rogler, Chrlstophe Chassard, Laura Berchtold, Fabienne Kurt, Michael Martin Schari, Marianne Rebecca Spalinger, Markus Relchin, Florian Nils Rosenthal, Marco Meola